Targeting of serglycin with siRNA in human myeloma cells decreased cell adhesion in vitro, tumour cell growth in vivo and vascularization when injected subcutaneously into immunocompromised CB17 SCID mice, suggesting an essential role for serglycin in tumour growth and vascularization[17]. The gene discussed is SRGN; the disease is neoplasm.